AQR Capital Management
TSHA icon

AQR Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

AQR Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$793K Buy
177,309
+8,447
+5% +$39.3K ﹤0.01% 2896
2025
Q4 		$929K Buy
168,862
+17,862
+12% +$86.7K ﹤0.01% 2601
2025
Q3 		$494K Buy
151,000
+15,234
+11% +$43.1K ﹤0.01% 2819
2025
Q2 		$314K Buy
135,766
+27,867
+26% +$60.5K ﹤0.01% 2854
2025
Q1 		$150K Buy
107,899
+82,545
+326% +$138K ﹤0.01% 2942
2024
Q4 		$43.9K Sell
25,354
-44,117
-64% -$91.5K ﹤0.01% 2818
2024
Q3 		$140K Buy
+69,471
New +$152K ﹤0.01% 2622
2022
Q3 		– Sell
-10,134
Closed -$38K – 2323
2022
Q2 		$38K Buy
+10,134
New +$40.2K ﹤0.01% 2146

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AQR Capital Management's TSHA Position: Q1 2026 in Review

AQR Capital Management increased its Taysha Gene Therapies (TSHA) stake by 5% in Q1 2026, buying an estimated $39.3K and bringing the position to 177,309 shares worth $793K. The position accounts for ﹤0.01% of the portfolio, ranked #2896.

AQR Capital Management first reported a position in TSHA in Q2 2022 and has held it in 8 quarters since. The position peaked at $929K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • AQR Capital Management held 177,309 shares of Taysha Gene Therapies worth $793K as of Q1 2026.
  • AQR Capital Management bought 8,447 Taysha Gene Therapies shares in Q1 2026, an estimated $39.3K.
  • Taysha Gene Therapies made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2896 holding.
  • AQR Capital Management first reported a position in Taysha Gene Therapies in Q2 2022 and has held it in 8 quarters since.
  • AQR Capital Management's Taysha Gene Therapies position peaked at $929K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.